Pfizer, Inc. (NYSE:PFE) has been given a $39.00 price objective by equities research analysts at Sanford C. Bernstein in a research note issued on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s target price indicates a potential upside of 9.70% from the stock’s current price.

Several other research firms also recently weighed in on PFE. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, August 14th. Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Thursday, August 24th. Berenberg Bank reissued a “hold” rating and issued a $36.00 price target (down from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Finally, BidaskClub downgraded shares of Pfizer from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 13th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average target price of $37.83.

Pfizer (NYSE:PFE) traded down 0.34% during mid-day trading on Tuesday, hitting $35.43. 4,519,460 shares of the stock were exchanged. The stock has a market cap of $210.71 billion, a PE ratio of 25.92 and a beta of 1.00. Pfizer has a 52-week low of $29.83 and a 52-week high of $35.84. The stock’s 50 day moving average is $33.71 and its 200 day moving average is $33.53.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the firm posted $0.64 earnings per share. Analysts forecast that Pfizer will post $2.56 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Pfizer, Inc. (PFE) Given a $39.00 Price Target by Sanford C. Bernstein Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/19/pfizer-inc-pfe-given-a-39-00-price-target-by-sanford-c-bernstein-analysts.html.

In related news, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $6,703,712.00. Following the completion of the transaction, the chief executive officer now owns 580,318 shares in the company, valued at $19,730,812. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock valued at $15,813,961 in the last 90 days. Company insiders own 0.06% of the company’s stock.

A number of institutional investors have recently modified their holdings of PFE. Asset Planning Services Ltd. lifted its stake in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 137 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new position in Pfizer in the second quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware purchased a new position in Pfizer in the second quarter worth approximately $103,000. D. Scott Neal Inc. lifted its stake in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the last quarter. Finally, Orrstown Financial Services Inc. lifted its stake in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 612 shares during the last quarter. Institutional investors own 69.00% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.